Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myasthenia Gravis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H2 2016', provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis - The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects - The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Myasthenia Gravis Overview 9 Therapeutics Development 10 Pipeline Products for Myasthenia Gravis - Overview 10 Pipeline Products for Myasthenia Gravis - Comparative Analysis 11 Myasthenia Gravis - Therapeutics under Development by Companies 12 Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 14 Myasthenia Gravis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Myasthenia Gravis - Products under Development by Companies 18 Myasthenia Gravis - Products under Investigation by Universities/Institutes 19 Myasthenia Gravis - Companies Involved in Therapeutics Development 20 Achillion Pharmaceuticals, Inc. 20 Alexion Pharmaceuticals, Inc. 21 Alpha Cancer Technologies Inc. 22 arGEN-X BV 23 Biokine Therapeutics Ltd. 24 BioMarin Pharmaceutical Inc. 25 CuraVac, Inc. 26 GlaxoSmithKline Plc 27 Grifols, S.A. 28 HanAll Biopharma Co., Ltd. 29 Karus Therapeutics Limited 30 Millennium Pharmaceuticals Inc 31 Neurotune AG 32 Novartis AG 33 Pfizer Inc. 34 ReceptoPharm, Inc. 35 Regenesance BV 36 Shire Plc 37 Toleranzia AB 38 Myasthenia Gravis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 ACT-101 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 amifampridine phosphate - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 ARGX-113 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BB-008 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 belimumab - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 BKT-130 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 bortezomib - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 CFZ-533 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 CVMG-01 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 eculizumab - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 GL-2045 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 HL-161 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 immune globulin (human) - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 KA-1463 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 methotrexate - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 NT-1654 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Recombinant Protein for Myasthenia Gravis - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 regenemab - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 RPI-78M - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 SM-201 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Vaccine for Myasthenia Gravis - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Vaccine for Myasthenia Gravis - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Myasthenia Gravis - Dormant Projects 101 Myasthenia Gravis - Discontinued Products 102 Myasthenia Gravis - Product Development Milestones 103 Featured News & Press Releases 103 Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 103 Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 105 Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis 107 Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe 107 Dec 09, 2015: Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis 107 May 29, 2015: Double recognition of Toleranzia 108 Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis 109 Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 109 Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 110 Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 111 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 111 Apr 24, 2014: Toleranzia supported by VINNOVA 112 Apr 24, 2013: arGEN-X Advances ARGX-113 Into Preclinical Development For Autoimmune Disorders 113 Sep 14, 2011: Phase II Study of Eculizumab In Patients With Severe And Refractory Generalized Myasthenia Gravis Presented At MGFA Annual Meeting 113 Aug 06, 2009: European Commission And U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation For The Treatment Of Atypical Hemolytic Uremic Syndrome (aHUS) 114 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for Myasthenia Gravis, H2 2016 10 Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 20 Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2016 21 Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc., H2 2016 22 Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2016 23 Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2016 24 Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc., H2 2016 25 Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2016 26 Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2016 27 Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2016 28 Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 29 Myasthenia Gravis - Pipeline by Karus Therapeutics Limited, H2 2016 30 Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 31 Myasthenia Gravis - Pipeline by Neurotune AG, H2 2016 32 Myasthenia Gravis - Pipeline by Novartis AG, H2 2016 33 Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2016 34 Myasthenia Gravis - Pipeline by ReceptoPharm, Inc., H2 2016 35 Myasthenia Gravis - Pipeline by Regenesance BV, H2 2016 36 Myasthenia Gravis - Pipeline by Shire Plc, H2 2016 37 Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2016 38 Assessment by Monotherapy Products, H2 2016 39 Number of Products by Stage and Target, H2 2016 41 Number of Products by Stage and Mechanism of Action, H2 2016 43 Number of Products by Stage and Route of Administration, H2 2016 45 Number of Products by Stage and Molecule Type, H2 2016 47 Myasthenia Gravis - Dormant Projects, H2 2016 101 Myasthenia Gravis - Discontinued Products, H2 2016 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
